Detailed price information for Rapport Therapeutics Inc (RAPP-Q) from The Globe and Mail including charting and trades.

Teacher Yareli Jessica Gijon tells PEOPLE how she manages epilepsy in the classroom and why she posted a seizure video to ...

Drug-resistant epilepsy affects millions of people worldwide and remains one of the most difficult neurological disorders to treat. For patients whose seizures continue despite medication, surgical ...

Ripon father Mark Mayatt-Simmons has cycled from Land’s End to John O’Groats, raising more than £2,300 for Leeds-based Epilepsy Action ...

Ripon father Mark Mayatt-Simmons has cycled from Land’s End to John O’Groats, raising more than £2,300 for Leeds-based ...

Xenon Pharmaceuticals (NASDAQ:XENE) said it is preparing to submit a new drug application to the U.S. Food and Drug ...

Angelini Pharma is acquiring Catalyst Pharmaceuticals in a $4.1 billion transaction that expands its presence in the US rare ...

Reported positive topline data from Phase 3 X-TOLE2 study of azetukalner in FOS in March and anticipate NDA submission in Q3 2026Five additional Phase 3 studies of azetukalner continue to enroll in ep ...

Reported positive topline data from Phase 3 X-TOLE2 study of azetukalner in FOS in March and anticipate NDA submission in Q3 2026Five additional ...

Consideration is set at $31.50 per Catalyst share in cash, implying an equity value above $4.1 billion and a 21% premium to ...

Epilepsy is a neurological disorder that causes temporary brain dysfunction. The aftermath of an epileptic seizure varies for each individual and depends on its severity. FITBOOK outlines types of ...

NeuroPace, Inc. , a medical device company focused on transforming the lives of people living with drug resistant epilepsy, today announced a major milestone in its clinical evidence program with the ...